Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.
Summary
A randomized, placebo-controlled phase 3 clinical trial investigated the addition of tucidinostat, a histone deacetylase inhibitor, to standard R-CHOP in patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). The study demonstrated a significant improvement in event-free survival (EFS) in the tucidinostat group, with a 28% lower risk of events and a two-year EFS rate of 60.3% versus 50.5% for the placebo group. The complete response rate was also higher (73.0% vs 61.8%). Although increased toxicity was observed with tucidinostat, it was generally manageable.
Analysis
This study is of paramount importance as it is the first to validate the efficacy of an epigenetic modulator as a first-line treatment for diffuse large B-cell lymphoma, specifically for the high-risk MYC/BCL2 double-expressor subtype. The integration of tucidinostat with R-CHOP offers a novel therapeutic approach that simultaneously targets these oncoproteins, significantly improving event-free survival. This could transform clinical practice for this high-risk patient population by providing a more effective and manageable treatment option than current alternatives.